Fig. 8.

Increased expression levels of the pyrimidine metabolic rate–limiting enzymes in lung cancer cells are induced by DNA amplification and TP53 mutation. a Oncoprints demonstrated the alteration frequency of pyrimidine metabolic rate–limiting enzymes in LUAD. Each line represented one patient. b Box plots demonstrated the expression levels of the pyrimidine metabolic rate limiting enzymes in patients with lung cancer. P values indicated the differences between patients with TP53 mutant and TP53 wild-type. c Heatmap demonstrated the expression levels of the pyrimidine metabolic rate–limiting enzymes in TP53 mutant and TP53 wild-type LUAD patients